Brocresine in Parkinson's disease: Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa
AUTOR(ES)
Howse, Patricia M.
RESUMO
Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease. The search for useful decarboxylase inhibitors therefore need not be limited to agents that do not pass the blood/brain barrier.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=494271Documentos Relacionados
- Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
- Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase
- Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
- Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study
- Parkinson's disease: a journey
